drugset / Trial / NCT05513131
Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML
NaSingle-groupOpen-labelTreatment
Summary
This research is being done to assess the therapeutic efficacy and safety of a promising regimen (Venetoclax combined with Azacitidine and Harringtonine) in patients with secondary AML This study involves the following: Venetoclax combined with Azacitidine and Harringtonine
Timeline
- Start
- 2021-09-30
- Primary completion
- 2023-09-30
- Completion
- 2025-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | — |
| Subject | Homoharringtonine | Small molecule | 2 mg | — |
| Subject | Venetoclax | Small molecule | 400 mg | — |